LONG TERM ORAL ETOPOSIDE AS SECOND LINE THERAPY IN RECURRENT EPITHELIAL CARCINOMA OF THE OVARY

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

MOUSAVI A.S.; TEHRANIAN A.; BEHTASH N.; MODARES GILANI M.; GHAEM MAGHAMI FATEMEH

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: ACTA MEDICA IRANICA Year:2006 | Volume:44 | Issue:1 Page(s): 7-12

Download Full-Text

View:

356

Download:

121

Cites:

Information Journal Paper

Title

LONG TERM ORAL ETOPOSIDE AS SECOND LINE THERAPY IN RECURRENT EPITHELIAL CARCINOMA OF THE OVARY

Author(s)

Keywords

ORAL ETOPOSIDE

RECURRENT EPITHELIAL OVARIAN CANCER

SECOND-LINE CHEMOTHERAPY

Abstract

There is a continuing need to identify new agents that are active in ovarian cancer. Etoposide is a derivative of the plant alkaloid epipodophyllotoxin. The availability of etoposide in oral preparation allows prolonged administration by the oral route. In this study, activity and toxicity of etoposide in women with recurrent ovarian cancer are described from a case series of women with recurrent ovarian cancer who had measurable disease. All patients had prior platinum-based chemotherapy and developed progressive disease. ORAL ETOPOSIDE was given as 50 mg/day for 21 days every 4 weeks until progression of disease or prohibitive toxicity. From December 1999 to January 2004, 32 patients were enrolled in this study. Thirty patients received a total of 133 cycles of etoposide. Median age of patients was 49 years (range, 19 to 75). The median number of etoposide cycles was 4 (range, 1 to 12). There were 5 partial responses (16.6%). The mean response duration was 4.8 months (range, 3.5 to 6); median progression-free interval was 7 months (range, 3 to 13) and median survival time was 12.5 months (range, 1.3 to 36). The major toxicity was leukopenia. One patient required red blood cell transfusions and the main non-hematologic toxicity was nausea and vomiting. There were no treatment-related mortalities. Although etoposide appears to exhibit modest activity in recurrent ovarian cancer after platinum-based therapy, response and survival durations are short.

Cites

No record.

References

Cite

APA: Copy

MOUSAVI, A.S., TEHRANIAN, A., BEHTASH, N., MODARES GILANI, M., & GHAEM MAGHAMI, FATEMEH. (2006). LONG TERM ORAL ETOPOSIDE AS SECOND LINE THERAPY IN RECURRENT EPITHELIAL CARCINOMA OF THE OVARY. ACTA MEDICA IRANICA, 44(1), 7-12. SID. https://sid.ir/paper/277873/en

Vancouver: Copy

MOUSAVI A.S., TEHRANIAN A., BEHTASH N., MODARES GILANI M., GHAEM MAGHAMI FATEMEH. LONG TERM ORAL ETOPOSIDE AS SECOND LINE THERAPY IN RECURRENT EPITHELIAL CARCINOMA OF THE OVARY. ACTA MEDICA IRANICA[Internet]. 2006;44(1):7-12. Available from: https://sid.ir/paper/277873/en

IEEE: Copy

A.S. MOUSAVI, A. TEHRANIAN, N. BEHTASH, M. MODARES GILANI, and FATEMEH GHAEM MAGHAMI, “LONG TERM ORAL ETOPOSIDE AS SECOND LINE THERAPY IN RECURRENT EPITHELIAL CARCINOMA OF THE OVARY,” ACTA MEDICA IRANICA, vol. 44, no. 1, pp. 7–12, 2006, [Online]. Available: https://sid.ir/paper/277873/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops